Transurethral Water Vapor Thermal Therapy and Transurethral Waterjet Ablation for Benign Prostatic Hyperplasia
Customize your policy alerts
Sign up for Premera Bluecross Policy 2.01.544 alerts
Get alerted when Policy 2.01.544 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical necessity and coverage criteria for transurethral water vapor thermal therapy and transurethral waterjet ablation (Aquablation) for benign prostatic hyperplasia with lower urinary tract obstruction. It guides providers submitting these services for coverage.
The 2026 annual review added refractory urinary retention secondary to BPH requiring an indwelling catheter or intermittent self-catheterization as a medical necessity pathway for both Rezum and Aquablation.
The prostate-volume criterion for transurethral waterjet ablation was expanded from greater than 30 mL and less than or equal to 80 mL to less than or equal to 150 mL.
The policy clarified that medical necessity is met solely when refractory urinary retention requiring catheterization is present or when the IPSS/AUASS is at least 12 and additional criteria are satisfied.
The policy title was updated to Transurethral Water Vapor Thermal Therapy and Transurethral Waterjet Ablation for Benign Prostatic Hyperplasia.
CPT code 52597 was added effective January 1, 2026.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.